Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Market Closed - Nasdaq Other stock markets 21:00:00 10/04/2026 BST			5-day change	1st Jan Change
65.14 ^USD	-1.65%		+6.73%	-1.88%

03-28	Arrowhead Pharmaceuticals Presents New Long-Term Efficacy And Safety Data For Plozasiran Across A Spectrum Of Hypertriglyceridemia	CI
03-25	Sarepta Therapeutics Announces First Clinical Data from Sirna Pipeline Targeting FSHD1 and DM1	CI

Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 02

Published on 06/09/2025 at 09:50 pm BST

S&P Capital IQ

Presenter Speech
Andrea Tan (Analysts)

Great. Thanks, everyone, for joining us. I'm Andrea Newkirk, one of the biotech analysts here at Goldman Sachs, and I'm really pleased to be joined by James

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Arrowhead Pharmaceuticals, Inc.

03-28	Arrowhead Pharmaceuticals Presents New Long-Term Efficacy And Safety Data For Plozasiran Across A Spectrum Of Hypertriglyceridemia	CI
03-25	Sarepta Therapeutics Announces First Clinical Data from Sirna Pipeline Targeting FSHD1 and DM1	CI
02-22	Certain Warrants of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI
02-22	Certain Options of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI
02-22	Certain Common Stock of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI
02-09	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400 - Biotechnology	CI
02-09	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400 Health Care	CI
02-09	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400	CI
02-09	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from S&P 600 Health Care	CI
02-09	Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from S&P 600	CI
02-06	Arrowhead Pharmaceuticals, Inc., Q1 2026 Earnings Call, Feb 05, 2026
02-05	Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q1 Revenue $264.0M, vs. FactSet Est of $213.9M	MT
02-05	Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q1 Revenue $264.0M, vs. FactSet Est of $213.9M	MT
02-05	Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
02-04	Ciena Set to Join S&P500	MT